Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

DURECT  (Stock symbol: DRRX )

10260 Bubb Road
Cupertino, CA 95014
Website Company Summary Management Team

Outside board: (May no longer be on the board) Simon Benito (Merck Former Division SVP) Terrence F Blaschke (Stanford University School of Medicine Professor) David Hoffmann (ALZA Pharmaceuticals Treasurer) Armand Nuekermans (Nortel Networks Division CTO) Jon S Saxe (PDL BioPharma)

Business description: DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is being developed for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIRĀ® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
Partners include: ALZA PharmaceuticalsCassava SciencesEndo Pharmaceuticals;  BioPartners;  NeuroSystec;  Nycomed

Rounds: 3
Recent Fundings:    Aug 1999
Capital raised: 29.4M
Last Round: 20.0M
Ownership: Public  
Stock Symbol: DRRX

Last Tweets


Last Mentions

Record updated: Jul 2022
Sector: Medical
Year Founded: 1998
Headcount: 101-150 as of Jul 2022
Rounds: 3
Recent Fundings:    Aug 1999
Capital Raised: 29.4M
Last Round: 20.0M
Ownership: Public  
Stock Symbol: DRRX